&nbsp;

Dec 2025

Regimen

ACAL

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

acalabrutinib - For the treatment of adult patients with chronic lymphocytic leukemia (CLL), based on criteria

Drugs Used:

acalabrutinib

Quick Link(s):

Regimen Monograph

Dec 2025

Dépistage du cancer du poumon

Drug

daratumumab

Other Name(s): Darzalex®

Quick Link(s):

Jan 2026

Drug

daratumumab (subcut)

Other Name(s): Darzalex® SC

Quick Link(s):

Jan 2026

Regimen

DARA

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Drugs Used:

daratumumab (Unfunded)

Quick Link(s):

Regimen Monograph

Jan 2026

Regimen

DARA(MNT)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Daratumumab in Combination with a Bortezomib-Based Regimen for Newly Diagnosed Transplant Ineligible Multiple Myeloma

Drugs Used:

daratumumab

Quick Link(s):

Regimen Monograph

Jan 2026

Regimen

DARA(MNT-SC)

Cancer Type:

Hematologic,

Amyloidosis,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Daratumumab in Combination with a Bortezomib-Based Regimen for Newly Diagnosed Transplant Ineligible Multiple Myeloma

New Drug Funding Program

Daratumumab - In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma

New Drug Funding Program

Daratumumab and Bortezomib in combo with Cyclophosphamide and Dexamethasone - Previously Untreated Light Chain (AL) Amyloidosis

Drugs Used:

daratumumab (subcut)

Quick Link(s):

Regimen Monograph

Jan 2026

Drug

DACTINomycin

Other Name(s): Cosmegen®

Quick Link(s):

Feb 2026

Drug

atezolizumab

Other Name(s): Tecentriq™

Quick Link(s):